Targeted inhibition of Multidrug Resistance-associated Protein 4 (MRP4) as a therapeutic strategy for childhood neuroblastoma

靶向抑制多药耐药相关蛋白 4 (MRP4) 作为儿童神经母细胞瘤的治疗策略

• 批准号: nhmrc : 1029543
• 负责人: Dr Jamie Fletcher
• 金额: $ 40.17万
• 依托单位: The University of New South Wales
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeted-inhibition-multidrug-childhood-neuroblastoma/110693
• 关键词: Targeted; inhibition; Multidrug; Resistance; associated

We have shown that a high tumour level of the gene, MRP4, confers a particularly poor outcome in children with the aggressive cancer neuroblastoma. Our results suggest that MRP4 can drive the growth of neuroblastoma cells, and that it does so by removing from the cancer cell a compound that normally regulates key cellular responses including survival and differentiation. We will explore this, and will also test promising inhibitors of MRP4 with therapeutic potential, that we have developed.

我们已经表明，高肿瘤水平的基因，MRP 4，赋予一个特别差的结果在儿童与侵略性癌症神经母细胞瘤。我们的研究结果表明，MRP4可以驱动神经母细胞瘤细胞的生长，并且它通过从癌细胞中去除一种通常调节关键细胞反应（包括存活和分化）的化合物来实现这一点。我们将探索这一点，并将测试我们开发的具有治疗潜力的有前途的MRP4抑制剂。